NCT04883177 is a clinical trial in COVID-19, sponsored by Hepatopancreatobiliary Surgery Institute of Gansu Province.

Who is sponsoring NCT04883177?

NCT04883177 is sponsored by Hepatopancreatobiliary Surgery Institute of Gansu Province.

What condition does NCT04883177 study?

NCT04883177 studies COVID-19, Liver Disease, Vaccine Reaction.

Is NCT04883177 still recruiting?

NCT04883177 is currently completed. Last updated 25 April 2023.

Last reviewed 2023-04-25 · How we verify

NCT04883177

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)

Completed Last updated 25 April 2023

What this trial tests

trial in COVID-19 in 1,000 participants. Completed in 1 May 2022.

Timeline

11 May 2021

Primary endpoint
1 January 2022

1 May 2022

Quick facts

Lead sponsor	Hepatopancreatobiliary Surgery Institute of Gansu Province
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	11 May 2021
Primary completion	1 January 2022
Estimated completion	1 May 2022
Sites	37 locations across China

Conditions studied

COVID-19 — all drugs for COVID-19 →
Liver Disease — all drugs for Liver Disease →
Vaccine Reaction — all drugs for Vaccine Reaction →

Sponsor

Hepatopancreatobiliary Surgery Institute of Gansu Province

Who can join

18 and older, any sex, with COVID-19 or Liver Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

COVID-19 pandemic with SARS-CoV-2 infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver disease are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. Therefore, early inoculation of SARS-CoV-2 vaccine in patients with liver disease is an important protective measure. However, information on the effectiveness and safety of the COVID-19 vaccine for liver disease remains to be determined. This muilticentre study (CHESS2101) aims to study the effectiveness and safety of the COVID-19 vaccination for patients with liver disease.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study.
Ai J, Wang J, Liu D, Xiang H, et al · · 2022 · cited 57× · PMID 34942370 · DOI 10.1016/j.cgh.2021.12.022
Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study.
Wang J, Zhang Q, Ai J, Liu D, et al · · 2022 · cited 18× · PMID 35403977 · DOI 10.1007/s12072-022-10332-9
Safety and immunogenicity of COVID-19 vaccination in patients with hepatocellular carcinoma (CHESS-NMCID 2101): A multicenter prospective study.
Qi X, Wang J, Zhang Q, Ai J, et al · · 2022 · cited 10× · PMID 35811309 · DOI 10.1002/jmv.27992
Safety and Efficacy of SARS-CoV-2 Vaccination in Patients with Chronic Liver Disease
Mao Y, Gao L, Li Y, Wang F. · · 2023

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Hepatopancreatobiliary Surgery Institute of Gansu Province trials

Trials by the same sponsor.

NCT03104569 — Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma · NA · not yet recruiting
NCT07321431 — The Optimal Measurement Time for the New Gallbladder Function Assessment Method · NA · recruiting
NCT07091526 — Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer · recruiting
NCT07039864 — A Novel Strategy for Evaluating Gallbladder Contraction Function by Ultrasound · NA · completed
NCT06697405 — Impact of Cardiopulmonary Bypass Time on Gastrointestinal Complications · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04883177 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hepatopancreatobiliary Surgery Institute of Gansu Province
Last refreshed: 25 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04883177.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing